{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-026391","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.089554+00:00","generated_at":"2026-05-24T08:30:19.955058+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CytoSorbents reschedules earnings call to March 31; reaffirms Q4 product revenue $9.0-$9.2M (22-25% growth)","bullets":["Earnings call rescheduled to March 31, 2025 at 4:30 PM ET; annual audit still in progress.","Q4 product revenue expected $9.0-$9.2M (+22-25% YoY); full-year product revenue $35.4-$35.6M (+14% YoY).","Q4 product gross margin ~70%, vs 61% prior quarter and 72% prior year.","Pro-forma cash balance at Dec 31, 2024 ~$17.0M (unrestricted $15.5M); net Q4 cash burn ~$2.5M.","DrugSorb-ATR marketing applications under FDA and Health Canada review; regulatory decisions expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-026391","json":"https://secwatch.observer/filing/0001104659-25-026391.json","markdown":"https://secwatch.observer/filing/0001104659-25-026391.md","text":"https://secwatch.observer/filing/0001104659-25-026391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925026391/0001104659-25-026391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925026391/tm259948d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T08:30:19.955058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}